Oseltamivir

Overview

Oseltamivir (Tamiflu®) is an antiviral drug classified as a neuraminidase inhibitor. It has been proposed as an adjunctive treatment for canine parvoviral enteritis and other viral infections with secondary bacterial involvement, although evidence supporting its clinical efficacy in veterinary patients remains limited.

The use of oseltamivir in veterinary medicine remains controversial because it is an important antiviral medication used for the treatment and prevention of influenza in humans. Concerns include preservation of drug availability for human use and the potential development of antiviral resistance.

Mechanism of Action (MOA): Oseltamivir phosphate is a prodrug that is converted after absorption to its active metabolite, oseltamivir carboxylate. The active metabolite competitively inhibits viral neuraminidase, an enzyme required for viral replication, release of virus from infected cells, and prevention of viral aggregation. It has also been proposed that oseltamivir may reduce the ability of canine parvovirus to penetrate intestinal mucosa and infect intestinal crypt cells, while potentially reducing gastrointestinal bacterial colonization, translocation, and toxin production. Canine parvovirus does not itself contain neuraminidase, so any observed benefit may instead reflect activity against bacterial neuraminidase from enteric bacteria associated with secondary infections rather than a direct effect on the virus.

Indications

Oseltamivir has been proposed for use as an adjunctive antiviral therapy in dogs, although supporting evidence remains limited.

• Canine parvoviral enteritis: Has been used adjunctively in canine parvovirus infection, but a small prospective, randomized, blinded, placebo-controlled trial found no significant reduction in hospitalization time, treatments needed, clinical scores, morbidity, or mortality. The dose is given in the Dosage section below.
• Viral infections with secondary bacterial involvement: Has been suggested as a supportive treatment option, although clinical experience and evidence are limited.

Dosage (Reference)

Dog

Oseltamivir has been used as an adjunctive treatment in dogs with canine parvoviral enteritis. Published veterinary dosing information remains limited.

Warnings & Precautions

Oseltamivir should be used cautiously in selected patients, and treatment should be initiated as early as possible when therapy is considered.

• Hypersensitivity: Contraindicated in patients with documented hypersensitivity to oseltamivir.
• Early treatment is essential: Treatment should begin as soon as possible. In humans with influenza, delay beyond 40 hours after the onset of clinical signs is associated with minimal efficacy.
• Renal impairment: Dosage adjustments may be necessary in patients with impaired renal function.
• Anaphylaxis and skin reactions: Severe hypersensitivity reactions, including anaphylaxis and skin reactions, have been reported in humans.
• Canine influenza: Oseltamivir is neither approved nor recommended for the treatment of canine influenza. It represents an important antiviral agent for human influenza management, and antiviral drugs as a class have not been tested for efficacy in canine influenza.
• Pregnancy and lactation: Safety has not been established in animals; use only when the potential maternal benefits outweigh the potential risks to offspring.
• Neonatal patients: Neurotoxicity is a potential concern in newborn animals based on experimental data.

Drug Interactions

Interactions with oseltamivir have either been reported or are theoretical in humans or animals, and may be of significance in veterinary patients. Concurrent use is not necessarily contraindicated, but weigh the potential risks and perform additional monitoring when appropriate.

• Probenecid: May approximately double exposure to the active metabolite (oseltamivir carboxylate) by reducing tubular secretion. This could potentially reduce the required dose or dosing frequency, but supporting data are not readily available.
• Live influenza vaccines: May reduce the immune response to live influenza virus vaccines.
• Inactivated influenza vaccines: No apparent effect on the response to killed influenza vaccines has been reported.
• Warfarin: May increase the risk of bleeding.

Side Effects & Overdose

Side Effects

The adverse effect profile of oseltamivir in veterinary patients has not been fully established. Available canine studies have not identified major treatment-related adverse effects.

• Nausea: One of the most commonly reported adverse effects in humans.
• Vomiting: Commonly reported in humans and may be reduced by administering the medication with food.
• Skin reactions: Serious dermatologic reactions, including erythema multiforme and toxic epidermal necrolysis, have been reported in humans.

Overdose

Oseltamivir has a relatively low toxic potential. In humans, reported overdoses have caused only nausea and vomiting.

• Nausea and vomiting: The signs reported following overdose in humans.
• Low acute toxicity: Human overdoses of up to 1000 mg have primarily resulted in gastrointestinal signs.
• Neurotoxicity risk in neonates: Brain concentrations of the prodrug were 1500 times greater, and the active metabolite 3 times higher, in neonatal rats given 1 g/kg than in adult rats; newborn puppies could exhibit similar findings, so neurotoxicity is a possibility.
• Management: For known or suspected overdose, consult a 24-hour poison control center that provides veterinary-specific information.

Key Notes

Practical clinical points that may help optimize the use of oseltamivir in dogs:

• Prodrug activation: Oseltamivir is administered as a prodrug and is hydrolyzed in the gastrointestinal tract and liver to its active metabolite, oseltamivir carboxylate.
• Antiviral resistance: Resistance to oseltamivir has been produced experimentally and has also been identified in post-treatment viral isolates from infected human patients.
• Administration with food: In humans, giving oseltamivir with food may reduce gastrointestinal effects.
• Role in current therapy: Antiviral drugs as a class have not yet been shown to be a critical part of canine parvovirus treatment, and current drug-of-choice guidance for parvoviral enteritis lists parenteral antibiotics and antiemetics rather than an antiviral. This is class-level guidance and does not name oseltamivir specifically.